Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI

Berger, Peter B.
July 2005
ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p11
Academic Journal
This article presents a study related to effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction (MI) presenting with ST-segment elevation. Several patients were presented with suspected acute MI and ST-segment elevation or new left bundle-branch block within 12 hours of symptom onset. Exclusion criteria included high risk for bleeding, recent major surgery or trauma, systolic blood pressure 180 mm Hg, severe anemia, hemorrhagic stroke within the past 12 months, oral anticoagulant therapy, heparin-induced thrombocytopenia, and pregnancy.


Related Articles

  • Acute Myocardial Infarction Caused by Delayed Heparin-Induced Thrombocytopenia and Acute Immunoreaction due to Re-exposure to Heparin in a Systemic Lupus Erythematosus Patient with HIT Antibodies. Suzuki, Shunji; Sakamoto, Susumu; Okada, Takeaki; Matsuo, Miyako; Saitoh, Atsushi; Matsuo, Takefumi // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p341 

    A patient with systemic lupus erythematosus and anti-cardiolipin antibodies and antibodies to platelet factor 4/heparin complexes suffered an acute myocardial infarction caused by delayed heparin-induced thrombocytopenia after heparin administration given to treat pulmonary hypertension....

  • ANTICOAGULANT THERAPY TODAY. Vigran, I. Myron // Angiology;Jan1964, Vol. 15 Issue 1, p1 

    A review has been presented of some of the more classical and recent findings in regard to results of anticoagulant therapy in acute myocardial infarction, the long-term prophylactic treatment of coronary artery disease, the use of anticoagulant therapy in cerebral vascular disease, as well as...

  • Antithrombotic Agents for Acute Coronary Syndromes. Mukherjee, Debabrata // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 2, p130 

    Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an...

  • Spotlight on Enoxaparin in ST-Segment Elevation Myocardial Infarction. Carter, Natalie J.; McCormack, Paul L.; Plosker, Greg L. // BioDrugs;2008, Vol. 22 Issue 5, p343 

    Enoxaparin (enoxaparin sodium; Lovenox) is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention. It binds to and...

  • Product Management and Efficacy Evaluation of an Anti-Coagulant Enoxaparin (Clexane) in Pakistan. Alam, Shazia; Naqvi, Syed; Gauhar, Shahnaz // Oman Medical Journal;Oct2009, Vol. 24 Issue 4, p264 

    Objective: Enoxaparin (Clexane) is a low molecular weight heparin with a molecular weight of around 4500D. It is a blood thinner used to treat pulmonary embolism, Deep vein thrombosis, unstable angina, non-ST elevated myocardial infarction and ST-segment elevation myocardial infarction. This...

  • Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions. Joost, Alexander; Kurowski, Volkhard; Radke, Peter W. // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1176 

    The administration of heparins (unfractionated or fractionated) represents the current standard as anticoagulant treatment during percutaneous coronary intervention in different clinical settings (elective cases and acute coronary syndrome). Since the incidence of heparin-induced...

  • Factor Xa Inactivation in Acute Coronary Syndrome. Barantke, Melanie; Bonnemeier, Hendrik // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1186 

    The increasing incidence of patients who develop acute coronary syndrome (ACS) stresses the importance of effective initial treatment to reduce morbidity and mortality. The recommended initial therapeutic regimen for patients with ACS includes both anticoagulants and antiplatelet agents to...

  • The Effect of Low Molecular Weight Heparin (Fragmin) on Myocardial Neutrophil Accumulation and Infarct Size in a Rat Model of Myocardial Infarction. Hasdai, David; Varda-Bloom, Nira; Blumberg, Nehemia; Ohad, Dan; Kornowski, Ran; Battler, Alexander // Angiology;May1996, Vol. 47 Issue 5, p491 

    Background: Heparin molecules possess immunomodulating properties, which are thought to complement their established antithrombotic activity. The purpose of this study was to evaluate whether the antiinflammatory properties of low molecular weight heparin (LMWH) can attenuate polymorphonuclear...

  • Prothrombin complex concentrate facilitates emergency spinal surgery in anticoagulated patients. Beynon, Christopher; Potzy, Anna; Unterberg, Andreas; Sakowitz, Oliver // Acta Neurochirurgica;Apr2014, Vol. 156 Issue 4, p741 

    Background: Oral anticoagulants are commonly used in the ageing population and therefore, spine surgeons are increasingly confronted with anticoagulated patients requiring surgical therapy. 'Bridging therapies' with heparins are established in elective settings, but the time frame for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics